2 mg
Sponsors
Kartos Therapeutics Inc., Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy, Day One Biopharmaceuticals Inc., Vaestra Goetalandsregionen, Vaestra Goetalandsregionen, The Pharmaceutical Company LEK-AM Sp. Zoo., Przedsiebiorstwo Farmaceutyczne Lek-Am Sp. z o.o.
Conditions
Chronic Kidney DiseaseCongenital myopathyMenopauseNicotine dependencePediatric low-grade glioma harboring an activating RAF alteration requiring first-line systemic therapyPrimary MyelofibrosisSecondary Myelofibrosis (including but not limited to myelofibrosis post-Polycythemia Vera or post-Essential Thrombocythemia)measure of overall cognitive functioning in chronic schizophrenia
Phase 3
A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
RecruitingCTIS2023-504724-25-00
Start: 2024-10-16Target: 126Updated: 2025-10-06
LOGGIC/FIREFLY-2: A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients with Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy
RecruitingCTIS2024-510742-13-00
Start: 2023-04-19Target: 245Updated: 2025-11-19
A randomized, double-blind, placebo-controlled, multicenter study evaluating the effect of a 12-week
DHEA combination of 20 mg and 2 mg prolonged-release melatonin on sleep quality and mood in
postmenopausal women.
RecruitingCTIS2024-520234-30-00
Start: 2024-11-30Target: 100Updated: 2025-05-13
Phase 4
Cytisine in prolonged dosage versus Nicotine Replacement Therapy in nicotine-dependent patients with Chronic Kidney Disease - single-center, randomized, non-inferiority clinical trial.
RecruitingCTIS2023-509235-39-00
Start: 2025-10-30Target: 292Updated: 2024-07-29
COMPIS - Congenital myopathy intervention study. An open-label, cross over, randomized, controlled study using salbutamol
CompletedCTIS2024-512027-36-00
Start: 2021-09-27End: 2025-03-17Target: 20Updated: 2024-10-28